| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 20.2 | 16.6 | 23.3 |
| Other income | 0.4 | 0.1 | 0.6 |
| Total income | 20.6 | 16.7 | 23.9 |
| Profit before exceptional items & tax | 1.5 | 5.5 | -1.3 |
| Profit before tax | 1.5 | 5.5 | -1.3 |
| Net profit | 1.5 | 5.5 | -1.5 |
| Operating margin | 7.3% | 32.9% | -5.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -72.70% |
|---|---|
| Revenue, year on year | -13.30% |
BSE results filing, NSE: BROOKS. Figures extracted from the filing.
Brooks Laboratories Ltd: key numbers
- Share price
- ₹59.01
- Market cap
- ₹173.8 Cr
- Revenue (annual)
- ₹85.74 Cr
- Net profit (annual)
- ₹24.58 Cr
- P/E (TTM)
- 13.2×Sector 50.4×
- Promoter holding
- 52.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Brooks Laboratories Ltd
All →Brooks Laboratories Management Change
Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.
Brooks Laboratories Annual General Meeting
Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026. Shareholders transacted ordinary business, including the adoption of financial statements and director appointments.
Brooks Laboratories Q1 FY27 Results: Net Loss of ₹1.8 Cr
Brooks Laboratories Ltd reported revenue from operations of ₹23 Cr (-9.8% YoY) and a net loss of ₹1.8 Cr for Q1 FY27.
- Key figure
- Net loss ₹1.8 Cr